Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Next-generation delivery technology for gene editing
Company stage: Pre-clinical
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Dublin, Ireland
Partners: ONK Therapeutics
Avectas develops its proprietary SOLUPORE® technology to genetically engineer T cells and natural killer (NK) cells to enable the next generation of gene-modified cell therapies. The company has established a collaboration with ONK Therapeutics, however, it yet has to disclose any proprietary or partnered therapeutic programmes.